P4HA2在促进肿瘤进展中的作用

doi:10.3760/cma.j.cn371439-20220623-00105

摘要/Abstract

摘要：

P4HA2是编码胶原蛋白脯氨酰4-羟化酶（C-P4H）的α亚基的重要基因之一,在多种肿瘤中过表达并促进肿瘤进展,其高表达与患者的不良预后相关。在不同肿瘤中,P4HA2可以促进肿瘤细胞增殖、迁移和侵袭能力,增加肿瘤干细胞群体的比例,以及促进肿瘤细胞免疫逃逸等。深入了解P4HA2在肿瘤进展中的作用,可为针对P4HA2预防或逆转肿瘤进展提供新的思路和见解。

关键词: 肿瘤, P4HA2, C-P4H

Abstract:

P4HA2, one of the important genes encoding the α subunit of collagen prolyl 4-hydroxylase （C-P4H）, is overexpressed in a variety of tumors and promotes tumor progression, and its high expression correlates with the poor prognosis of patients. In different tumors, P4HA2 can promote the proliferation, migration and invasion of tumor cells, increase the proportion of cancer stem cell population, and promote tumor cells to escape from immune system. An in-depth understanding of the role of P4HA2 in tumor progression may provide new ideas and insights for targeting P4HA2 to prevent or reverse tumor progression.

Key words: Neoplasms, P4HA2, C-P4H

宋玉丽, 张颐. P4HA2在促进肿瘤进展中的作用[J]. 国际肿瘤学杂志, 2022, 49(9): 543-545.

Song Yuli, Zhang Yi. Role of P4HA2 in promoting cancer progression[J]. Journal of International Oncology, 2022, 49(9): 543-545.

参考文献 32

[1]	Shi R, Gao S, Zhang J, et al. Collagen prolyl 4-hydroxylases modify tumor progression[J]. Acta Biochim Biophys Sin (Shanghai), 2021, 53(7): 805-814. DOI: 10.1093/abbs/gmab065. doi: 10.1093/abbs/gmab065
[2]	Kisoda S, Shao W, Fujiwara N, et al. Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis[J]. Oral Dis, 2020, 26(6): 1149-1156. DOI: 10.1111/odi.13351. doi: 10.1111/odi.13351
[3]	Shang C, Huang J, Guo H. Identification of an metabolic related risk signature predicts prognosis in cervical cancer and correlates with immune infiltration[J]. Front Cell Dev Biol, 2021, 9: 677831. DOI: 10.3389/fcell.2021.677831. doi: 10.3389/fcell.2021.677831
[4]	Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021. DOI: 10.1002/ijc.33588. doi: 10.1002/ijc.33588
[5]	Rakovitch E, Sutradhar R, Nofech-Mozes S, et al. 21-gene assay and breast cancer mortality in ductal carcinoma in situ[J]. J Natl Cancer Inst, 2021, 113(5): 572-579. DOI: 10.1093/jnci/djaa179. doi: 10.1093/jnci/djaa179 pmid: 33369631
[6]	Toss MS, Miligy IM, Gorringe KL, et al. Prolyl-4-hydroxylase a subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS)[J]. Br J Cancer, 2018, 119(12): 1518-1526. DOI: 10.1038/s41416-018-0337-x. doi: 10.1038/s41416-018-0337-x
[7]	Agahozo MC, van Bockstal M, Westenend PJ, et al. Stromal changes are associated with high P4HA2 expression in ductal carcinoma in situ of the breast[J]. J Mammary Gland Biol Neoplasia, 2021, 26(4): 367-375. DOI: 10.1007/s10911-021-09504-4. doi: 10.1007/s10911-021-09504-4
[8]	Li M, Wang Q, Zheng Q, et al. Prognostic and diagnostic roles of prolyl 4-hydroxylase subunit α members in breast cancer[J]. Biomark Med, 2021, 15(13): 1085-1095. DOI: 10.2217/bmm-2020-0323. doi: 10.2217/bmm-2020-0323 pmid: 34387118
[9]	Kay EJ, Paterson K, Riera-Domingo C, et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix[J]. Nat Metab, 2022, 4(6): 693-710. DOI: 10.1038/s42255-022-00582-0. doi: 10.1038/s42255-022-00582-0 pmid: 35760868
[10]	Xiong G, Deng L, Zhu J, et al. Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition[J]. BMC Cancer, 2014, 14: 1. DOI: 10.1186/1471-2407-14-1. doi: 10.1186/1471-2407-14-1 pmid: 24383403
[11]	Liu M, Liu Y, Deng L, et al. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer[J]. Mol Cancer, 2018, 17(1): 65. DOI: 10.1186/s12943-018-0809-x. doi: 10.1186/s12943-018-0809-x pmid: 29471829
[12]	Wang J, Wang Y, Xing P, et al. Development and validation of a hypoxia-related prognostic signature for breast cancer[J]. Oncol Lett, 2020, 20(2): 1906-1914. DOI: 10.3892/ol.2020.11733. doi: 10.3892/ol.2020.11733 pmid: 32724434
[13]	Gilkes DM, Bajpai S, Chaturvedi P, et al. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts[J]. J Biol Chem, 2013, 288(15): 10819-10829. DOI: 10.1074/jbc.M112.442939. doi: 10.1074/jbc.M112.442939 pmid: 23423382
[14]	Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications[J]. Mol Aspects Med, 2019, 65: 2-15. DOI: 10.1016/j.mam.2018.06.003. doi: S0098-2997(18)30038-4 pmid: 29958900
[15]	Lei Y, Yan W, Lin Z, et al. Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma[J]. J Cell Mol Med, 2021, 25(1): 448-462. DOI: 10.1111/jcmm.16099. doi: 10.1111/jcmm.16099 pmid: 33215860
[16]	Feng GX, Li J, Yang Z, et al. Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA[J]. Oncogene, 2017, 36(50): 6895-6905. DOI: 10.1038/onc.2017.291. doi: 10.1038/onc.2017.291 pmid: 28846110
[17]	Yi M, Feng X, Peng W, et al. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease[J]. Eur J Clin Pharmacol, 2022, 78(4): 647-656. DOI: 10.1007/s00228-021-03247-1. doi: 10.1007/s00228-021-03247-1 pmid: 35032181
[18]	Wang T, Fu X, Jin T, et al. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma[J]. EBioMedicine, 2019, 45: 168-180. DOI: 10.1016/j.ebiom.2019.06.048. doi: S2352-3964(19)30429-3 pmid: 31278071
[19]	Martínez-Rodríguez F, Limones-González JE, Mendoza-Almanza B, et al. Understanding cervical cancer through proteomics[J]. Cells, 2021, 10(8): 1854. DOI: 10.3390/cells10081854. doi: 10.3390/cells10081854
[20]	Zhang Z, Chen F, Li S, et al. ERG the modulates Warburg effect and tumor progression in cervical cancer[J]. Biochem Biophys Res Commun, 2020, 522(1): 191-197. DOI: 10.1016/j.bbrc.2019.11.079. doi: 10.1016/j.bbrc.2019.11.079
[21]	Rashmi R, Huang X, Floberg JM, et al. Radioresistant cervical cancers are sensitive to inhibition of glycolysis and redox metabolism[J]. Cancer Res, 2018, 78(6): 1392-1403. DOI: 10.1158/0008-5472.CAN-17-2367. doi: 10.1158/0008-5472.CAN-17-2367 pmid: 29339540
[22]	Li Q, Wang Q, Zhang Q, et al. Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer[J]. Am J Transl Res, 2019, 11(11): 6938-6951. pmid: 31814898
[23]	Cao Y, Han Q, Li J, et al. P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition[J]. J Cancer, 2020, 11(10): 2788-2799. DOI: 10.7150/jca.38401. doi: 10.7150/jca.38401 pmid: 32226497
[24]	Mody MD, Rocco JW, Yom SS, et al. Head and neck cancer[J]. Lancet, 2021, 398(10318): 2289-2299. DOI: 10.1016/S0140-6736(21)01550-6. doi: 10.1016/S0140-6736(21)01550-6 pmid: 34562395
[25]	Lee DY, Abraham J, Ross E, et al. Rapid recurrence in head and neck cancer: underappreciated problem with poor outcome[J]. Head Neck, 2021, 43(1): 212-222. DOI: 10.1002/hed.26479. doi: 10.1002/hed.26479
[26]	Yang XH, Zhang XX, Jing Y, et al. Amino acids signatures of distance-related surgical margins of oral squamous cell carcinoma[J]. EBioMedicine, 2019, 48: 81-91. DOI: 10.1016/j.ebiom.2019.10.005. doi: 10.1016/j.ebiom.2019.10.005
[27]	Reis PP, Tokar T, Goswami RS, et al. A 4-gene signature from histologically normal surgical margins predicts local recurrence in patients with oral carcinoma: clinical validation[J]. Sci Rep, 2020, 10(1): 1713. DOI: 10.1038/s41598-020-58688-y. doi: 10.1038/s41598-020-58688-y pmid: 32015424
[28]	Schmidt S, Linge A, Zwanenburg A, et al. Development and validation of a gene signature for patients with head and neck carcinomas treated by postoperative Radio(chemo) therapy[J]. Clin Cancer Res, 2018, 24(6): 1364-1374. DOI: 10.1158/1078-0432.CCR-17-2345. doi: 10.1158/1078-0432.CCR-17-2345 pmid: 29298797
[29]	Ghouzlani A, Kandoussi S, Tall M, et al. Immune checkpoint inhibitors in human glioma microenvironment[J]. Front Immunol, 2021, 12: 679425. DOI: 10.3389/fimmu.2021.679425. doi: 10.3389/fimmu.2021.679425
[30]	Thakur A, Faujdar C, Sharma R, et al. Glioblastoma: current status, emerging targets, and recent advances[J]. J Med Chem, 2022, 65(13): 8596-8685. DOI: 10.1021/acs.jmedchem.1c01946. doi: 10.1021/acs.jmedchem.1c01946 pmid: 35786935
[31]	Zhang M, Zhou Z, Liu Z, et al. Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis[J]. PeerJ, 2022, 10: e12768. DOI: 10.7717/peerj.12768. doi: 10.7717/peerj.12768
[32]	Lin J, Jiang L, Wang X, et al. P4HA2 promotes Epithelial-to-mesenchymal transition and glioma malignancy through the collagen-dependent PI3K/AKT pathway[J]. J Oncol, 2021, 2021: 1406853. DOI: 10.1155/2021/1406853. doi: 10.1155/2021/1406853